nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—MAOA—nerve—acquired immunodeficiency syndrome	0.00689	0.099	CbGeAlD
Naratriptan—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00571	0.0819	CbGeAlD
Naratriptan—MAOA—blood plasma—acquired immunodeficiency syndrome	0.00521	0.0748	CbGeAlD
Naratriptan—HTR1F—nervous system—acquired immunodeficiency syndrome	0.00513	0.0737	CbGeAlD
Naratriptan—HTR1F—central nervous system—acquired immunodeficiency syndrome	0.00494	0.0709	CbGeAlD
Naratriptan—HTR1F—brain—acquired immunodeficiency syndrome	0.00392	0.0563	CbGeAlD
Naratriptan—HTR1F—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.00311	0.0405	CbGpPWpGaD
Naratriptan—MAOA—retina—acquired immunodeficiency syndrome	0.00285	0.041	CbGeAlD
Naratriptan—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.0025	0.0358	CbGeAlD
Naratriptan—HTR1B—nervous system—acquired immunodeficiency syndrome	0.0021	0.0302	CbGeAlD
Naratriptan—HTR1D—nervous system—acquired immunodeficiency syndrome	0.00204	0.0292	CbGeAlD
Naratriptan—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.00202	0.0291	CbGeAlD
Naratriptan—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.00201	0.0289	CbGeAlD
Naratriptan—MAOA—digestive system—acquired immunodeficiency syndrome	0.002	0.0288	CbGeAlD
Naratriptan—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.00196	0.0281	CbGeAlD
Naratriptan—MAOA—blood—acquired immunodeficiency syndrome	0.00191	0.0274	CbGeAlD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00191	0.0249	CbGpPWpGaD
Naratriptan—MAOA—spinal cord—acquired immunodeficiency syndrome	0.00184	0.0264	CbGeAlD
Naratriptan—MAOA—vagina—acquired immunodeficiency syndrome	0.00177	0.0254	CbGeAlD
Naratriptan—HTR1A—nervous system—acquired immunodeficiency syndrome	0.0017	0.0244	CbGeAlD
Naratriptan—MAOA—lung—acquired immunodeficiency syndrome	0.00167	0.024	CbGeAlD
Naratriptan—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.00163	0.0235	CbGeAlD
Naratriptan—HTR1B—brain—acquired immunodeficiency syndrome	0.00161	0.0231	CbGeAlD
Naratriptan—HTR1D—brain—acquired immunodeficiency syndrome	0.00156	0.0223	CbGeAlD
Naratriptan—MAOA—nervous system—acquired immunodeficiency syndrome	0.00155	0.0223	CbGeAlD
Naratriptan—MAOA—central nervous system—acquired immunodeficiency syndrome	0.00149	0.0214	CbGeAlD
Naratriptan—HTR1F—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00145	0.019	CbGpPWpGaD
Naratriptan—HTR1A—brain—acquired immunodeficiency syndrome	0.0013	0.0186	CbGeAlD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00122	0.0159	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00119	0.0156	CbGpPWpGaD
Naratriptan—MAOA—brain—acquired immunodeficiency syndrome	0.00118	0.017	CbGeAlD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00116	0.0151	CbGpPWpGaD
Naratriptan—MAOA—lymph node—acquired immunodeficiency syndrome	0.00114	0.0164	CbGeAlD
Naratriptan—HTR1F—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.00112	0.0146	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00105	0.0136	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000929	0.0121	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00091	0.0119	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00091	0.0119	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00088	0.0115	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000812	0.0106	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000796	0.0104	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000764	0.00997	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000764	0.00997	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000754	0.00984	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000746	0.00973	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000739	0.00965	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000724	0.00945	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000714	0.00932	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000709	0.00925	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000693	0.00905	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000669	0.00873	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000655	0.00855	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000646	0.00843	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000607	0.00793	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000607	0.00793	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000581	0.00758	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000563	0.00735	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000551	0.0072	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000551	0.0072	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000544	0.0071	CbGpPWpGaD
Naratriptan—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00053	0.000621	CcSEcCtD
Naratriptan—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.00053	0.000621	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.00053	0.000621	CcSEcCtD
Naratriptan—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000527	0.000618	CcSEcCtD
Naratriptan—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000527	0.000618	CcSEcCtD
Naratriptan—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000527	0.000617	CcSEcCtD
Naratriptan—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000527	0.000617	CcSEcCtD
Naratriptan—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000526	0.000616	CcSEcCtD
Naratriptan—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000526	0.000616	CcSEcCtD
Naratriptan—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000524	0.000614	CcSEcCtD
Naratriptan—HTR1F—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000523	0.00683	CbGpPWpGaD
Naratriptan—Rash—Didanosine—acquired immunodeficiency syndrome	0.000523	0.000612	CcSEcCtD
Naratriptan—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000523	0.000612	CcSEcCtD
Naratriptan—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000523	0.000612	CcSEcCtD
Naratriptan—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000522	0.000612	CcSEcCtD
Naratriptan—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000522	0.000612	CcSEcCtD
Naratriptan—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00052	0.000609	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000519	0.00678	CbGpPWpGaD
Naratriptan—Headache—Didanosine—acquired immunodeficiency syndrome	0.000519	0.000608	CcSEcCtD
Naratriptan—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000519	0.000608	CcSEcCtD
Naratriptan—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000518	0.000607	CcSEcCtD
Naratriptan—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000518	0.000606	CcSEcCtD
Naratriptan—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000517	0.000606	CcSEcCtD
Naratriptan—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000517	0.000606	CcSEcCtD
Naratriptan—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000516	0.000605	CcSEcCtD
Naratriptan—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000516	0.000605	CcSEcCtD
Naratriptan—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000516	0.000604	CcSEcCtD
Naratriptan—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000515	0.000604	CcSEcCtD
Naratriptan—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000515	0.000603	CcSEcCtD
Naratriptan—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000514	0.000603	CcSEcCtD
Naratriptan—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000513	0.000601	CcSEcCtD
Naratriptan—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000511	0.000598	CcSEcCtD
Naratriptan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000511	0.000598	CcSEcCtD
Naratriptan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00051	0.000598	CcSEcCtD
Naratriptan—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000509	0.000597	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000509	0.00665	CbGpPWpGaD
Naratriptan—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000509	0.000596	CcSEcCtD
Naratriptan—HTR1B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000509	0.00664	CbGpPWpGaD
Naratriptan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000509	0.000596	CcSEcCtD
Naratriptan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000508	0.000595	CcSEcCtD
Naratriptan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000507	0.000594	CcSEcCtD
Naratriptan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000507	0.000594	CcSEcCtD
Naratriptan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000506	0.000592	CcSEcCtD
Naratriptan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000506	0.000592	CcSEcCtD
Naratriptan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000504	0.000591	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000502	0.000588	CcSEcCtD
Naratriptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000502	0.000588	CcSEcCtD
Naratriptan—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000502	0.000588	CcSEcCtD
Naratriptan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000501	0.000587	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000501	0.000587	CcSEcCtD
Naratriptan—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000501	0.000586	CcSEcCtD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000499	0.00651	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000498	0.00651	CbGpPWpGaD
Naratriptan—Pain—Indinavir—acquired immunodeficiency syndrome	0.000498	0.000583	CcSEcCtD
Naratriptan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000498	0.000583	CcSEcCtD
Naratriptan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000497	0.000582	CcSEcCtD
Naratriptan—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000497	0.000582	CcSEcCtD
Naratriptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000496	0.000581	CcSEcCtD
Naratriptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000495	0.000579	CcSEcCtD
Naratriptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000494	0.000579	CcSEcCtD
Naratriptan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000494	0.000578	CcSEcCtD
Naratriptan—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000494	0.000578	CcSEcCtD
Naratriptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000493	0.000577	CcSEcCtD
Naratriptan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000493	0.000577	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000492	0.00642	CbGpPWpGaD
Naratriptan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000492	0.000576	CcSEcCtD
Naratriptan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000492	0.000576	CcSEcCtD
Naratriptan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000491	0.000575	CcSEcCtD
Naratriptan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00049	0.000575	CcSEcCtD
Naratriptan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00049	0.000574	CcSEcCtD
Naratriptan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000489	0.000572	CcSEcCtD
Naratriptan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000488	0.000572	CcSEcCtD
Naratriptan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000488	0.000572	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000488	0.00638	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000488	0.00638	CbGpPWpGaD
Naratriptan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000487	0.00057	CcSEcCtD
Naratriptan—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000486	0.00057	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000486	0.00634	CbGpPWpGaD
Naratriptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000485	0.000568	CcSEcCtD
Naratriptan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000483	0.000565	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000482	0.00629	CbGpPWpGaD
Naratriptan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000481	0.000563	CcSEcCtD
Naratriptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00048	0.000562	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000479	0.000561	CcSEcCtD
Naratriptan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000479	0.000561	CcSEcCtD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000478	0.00624	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000478	0.00624	CbGpPWpGaD
Naratriptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000478	0.000559	CcSEcCtD
Naratriptan—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000478	0.000559	CcSEcCtD
Naratriptan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000477	0.000559	CcSEcCtD
Naratriptan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000477	0.000559	CcSEcCtD
Naratriptan—HTR1D—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000477	0.00622	CbGpPWpGaD
Naratriptan—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000476	0.000558	CcSEcCtD
Naratriptan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000476	0.000558	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000475	0.000556	CcSEcCtD
Naratriptan—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000474	0.000555	CcSEcCtD
Naratriptan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000474	0.000555	CcSEcCtD
Naratriptan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000474	0.000555	CcSEcCtD
Naratriptan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000472	0.000553	CcSEcCtD
Naratriptan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000472	0.000553	CcSEcCtD
Naratriptan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000472	0.000553	CcSEcCtD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000472	0.00616	CbGpPWpGaD
Naratriptan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00047	0.000551	CcSEcCtD
Naratriptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00047	0.000551	CcSEcCtD
Naratriptan—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00047	0.000551	CcSEcCtD
Naratriptan—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00047	0.000551	CcSEcCtD
Naratriptan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00047	0.00055	CcSEcCtD
Naratriptan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000469	0.000549	CcSEcCtD
Naratriptan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000469	0.000549	CcSEcCtD
Naratriptan—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000468	0.000548	CcSEcCtD
Naratriptan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000468	0.000548	CcSEcCtD
Naratriptan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000467	0.000547	CcSEcCtD
Naratriptan—HTR1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000467	0.00609	CbGpPWpGaD
Naratriptan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000466	0.000546	CcSEcCtD
Naratriptan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000466	0.000546	CcSEcCtD
Naratriptan—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000465	0.000545	CcSEcCtD
Naratriptan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000464	0.000544	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000462	0.00604	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000462	0.00604	CbGpPWpGaD
Naratriptan—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000462	0.000541	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000462	0.00603	CbGpPWpGaD
Naratriptan—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000461	0.00054	CcSEcCtD
Naratriptan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.00046	0.000539	CcSEcCtD
Naratriptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00046	0.000539	CcSEcCtD
Naratriptan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000459	0.000538	CcSEcCtD
Naratriptan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000459	0.000538	CcSEcCtD
Naratriptan—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000458	0.000537	CcSEcCtD
Naratriptan—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000458	0.000536	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000457	0.00596	CbGpPWpGaD
Naratriptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000456	0.000534	CcSEcCtD
Naratriptan—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000455	0.000533	CcSEcCtD
Naratriptan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000455	0.000533	CcSEcCtD
Naratriptan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000455	0.000533	CcSEcCtD
Naratriptan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000455	0.000532	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000454	0.000532	CcSEcCtD
Naratriptan—Rash—Stavudine—acquired immunodeficiency syndrome	0.000454	0.000532	CcSEcCtD
Naratriptan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000454	0.000531	CcSEcCtD
Naratriptan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000453	0.000531	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000453	0.00592	CbGpPWpGaD
Naratriptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000453	0.000531	CcSEcCtD
Naratriptan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000453	0.00053	CcSEcCtD
Naratriptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000452	0.00053	CcSEcCtD
Naratriptan—HTR1F—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000452	0.0059	CbGpPWpGaD
Naratriptan—Headache—Stavudine—acquired immunodeficiency syndrome	0.000451	0.000528	CcSEcCtD
Naratriptan—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000451	0.000528	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000451	0.00588	CbGpPWpGaD
Naratriptan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00045	0.000528	CcSEcCtD
Naratriptan—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00045	0.000527	CcSEcCtD
Naratriptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00045	0.000527	CcSEcCtD
Naratriptan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000449	0.000526	CcSEcCtD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000447	0.00584	CbGpPWpGaD
Naratriptan—Rash—Abacavir—acquired immunodeficiency syndrome	0.000447	0.000524	CcSEcCtD
Naratriptan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000447	0.000523	CcSEcCtD
Naratriptan—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000447	0.000523	CcSEcCtD
Naratriptan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000447	0.000523	CcSEcCtD
Naratriptan—Headache—Abacavir—acquired immunodeficiency syndrome	0.000444	0.00052	CcSEcCtD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000444	0.00579	CbGpPWpGaD
Naratriptan—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000444	0.00052	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000443	0.000519	CcSEcCtD
Naratriptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000443	0.000519	CcSEcCtD
Naratriptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000443	0.000518	CcSEcCtD
Naratriptan—HTR1F—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00044	0.00575	CbGpPWpGaD
Naratriptan—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000439	0.000515	CcSEcCtD
Naratriptan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000438	0.000513	CcSEcCtD
Naratriptan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000437	0.000512	CcSEcCtD
Naratriptan—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000437	0.000512	CcSEcCtD
Naratriptan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000437	0.000512	CcSEcCtD
Naratriptan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000437	0.000512	CcSEcCtD
Naratriptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000435	0.000509	CcSEcCtD
Naratriptan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000434	0.000508	CcSEcCtD
Naratriptan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000434	0.000508	CcSEcCtD
Naratriptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000433	0.000508	CcSEcCtD
Naratriptan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000432	0.000507	CcSEcCtD
Naratriptan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000432	0.000506	CcSEcCtD
Naratriptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000429	0.000502	CcSEcCtD
Naratriptan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000429	0.000502	CcSEcCtD
Naratriptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000428	0.000501	CcSEcCtD
Naratriptan—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000428	0.000501	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000427	0.0005	CcSEcCtD
Naratriptan—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000421	0.000493	CcSEcCtD
Naratriptan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00042	0.000492	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00042	0.000492	CcSEcCtD
Naratriptan—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00042	0.00548	CbGpPWpGaD
Naratriptan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000419	0.000491	CcSEcCtD
Naratriptan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000418	0.000489	CcSEcCtD
Naratriptan—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000417	0.000489	CcSEcCtD
Naratriptan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000417	0.000489	CcSEcCtD
Naratriptan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000417	0.000489	CcSEcCtD
Naratriptan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000416	0.000488	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000416	0.00543	CbGpPWpGaD
Naratriptan—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000416	0.000487	CcSEcCtD
Naratriptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000416	0.000487	CcSEcCtD
Naratriptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000416	0.000487	CcSEcCtD
Naratriptan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000414	0.000485	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000413	0.00539	CbGpPWpGaD
Naratriptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000412	0.000482	CcSEcCtD
Naratriptan—HTR1F—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000409	0.00533	CbGpPWpGaD
Naratriptan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000407	0.000477	CcSEcCtD
Naratriptan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000405	0.000474	CcSEcCtD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000404	0.00528	CbGpPWpGaD
Naratriptan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000404	0.000473	CcSEcCtD
Naratriptan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000404	0.000473	CcSEcCtD
Naratriptan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000401	0.00047	CcSEcCtD
Naratriptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000401	0.00047	CcSEcCtD
Naratriptan—Pain—Saquinavir—acquired immunodeficiency syndrome	0.0004	0.000469	CcSEcCtD
Naratriptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.0004	0.000469	CcSEcCtD
Naratriptan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000398	0.000466	CcSEcCtD
Naratriptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000398	0.000466	CcSEcCtD
Naratriptan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000398	0.000466	CcSEcCtD
Naratriptan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000397	0.000465	CcSEcCtD
Naratriptan—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000395	0.000462	CcSEcCtD
Naratriptan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000394	0.000462	CcSEcCtD
Naratriptan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000394	0.000462	CcSEcCtD
Naratriptan—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000392	0.000459	CcSEcCtD
Naratriptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000389	0.000456	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000388	0.00507	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000388	0.00507	CbGpPWpGaD
Naratriptan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000388	0.000454	CcSEcCtD
Naratriptan—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000387	0.00506	CbGpPWpGaD
Naratriptan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000386	0.000453	CcSEcCtD
Naratriptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000386	0.000452	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000386	0.000452	CcSEcCtD
Naratriptan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000385	0.000451	CcSEcCtD
Naratriptan—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000385	0.000451	CcSEcCtD
Naratriptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000385	0.00045	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000383	0.005	CbGpPWpGaD
Naratriptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000382	0.000447	CcSEcCtD
Naratriptan—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000382	0.000447	CcSEcCtD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00038	0.00496	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00038	0.00496	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00038	0.00496	CbGpPWpGaD
Naratriptan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000377	0.000442	CcSEcCtD
Naratriptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000376	0.000441	CcSEcCtD
Naratriptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000372	0.000436	CcSEcCtD
Naratriptan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000372	0.000436	CcSEcCtD
Naratriptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000372	0.000435	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000372	0.00485	CbGpPWpGaD
Naratriptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.00037	0.000434	CcSEcCtD
Naratriptan—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00037	0.000433	CcSEcCtD
Naratriptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000368	0.000431	CcSEcCtD
Naratriptan—Rash—Indinavir—acquired immunodeficiency syndrome	0.000367	0.00043	CcSEcCtD
Naratriptan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000367	0.000429	CcSEcCtD
Naratriptan—Headache—Indinavir—acquired immunodeficiency syndrome	0.000365	0.000427	CcSEcCtD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000364	0.00476	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000364	0.00476	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000364	0.00475	CbGpPWpGaD
Naratriptan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000364	0.000426	CcSEcCtD
Naratriptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00036	0.000422	CcSEcCtD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00036	0.00469	CbGpPWpGaD
Naratriptan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000358	0.00042	CcSEcCtD
Naratriptan—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000356	0.00464	CbGpPWpGaD
Naratriptan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000355	0.000416	CcSEcCtD
Naratriptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000353	0.000414	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000352	0.00459	CbGpPWpGaD
Naratriptan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00035	0.000409	CcSEcCtD
Naratriptan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000349	0.000409	CcSEcCtD
Naratriptan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000348	0.000407	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000348	0.00454	CbGpPWpGaD
Naratriptan—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000347	0.000406	CcSEcCtD
Naratriptan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000346	0.000406	CcSEcCtD
Naratriptan—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000346	0.000405	CcSEcCtD
Naratriptan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.000404	CcSEcCtD
Naratriptan—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000344	0.000403	CcSEcCtD
Naratriptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000344	0.000403	CcSEcCtD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000341	0.00445	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000341	0.00445	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000338	0.00441	CbGpPWpGaD
Naratriptan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000336	0.000393	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000335	0.00437	CbGpPWpGaD
Naratriptan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000334	0.000392	CcSEcCtD
Naratriptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000333	0.00039	CcSEcCtD
Naratriptan—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000332	0.000388	CcSEcCtD
Naratriptan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000331	0.000388	CcSEcCtD
Naratriptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000331	0.000388	CcSEcCtD
Naratriptan—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00033	0.000386	CcSEcCtD
Naratriptan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000329	0.000385	CcSEcCtD
Naratriptan—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000328	0.00428	CbGpPWpGaD
Naratriptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000327	0.000383	CcSEcCtD
Naratriptan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.000377	CcSEcCtD
Naratriptan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00032	0.000375	CcSEcCtD
Naratriptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00032	0.000375	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000317	0.00414	CbGpPWpGaD
Naratriptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000316	0.00037	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000315	0.00411	CbGpPWpGaD
Naratriptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000312	0.000366	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000311	0.00406	CbGpPWpGaD
Naratriptan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.000363	CcSEcCtD
Naratriptan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000309	0.000362	CcSEcCtD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000308	0.00402	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000308	0.00402	CbGpPWpGaD
Naratriptan—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.000359	CcSEcCtD
Naratriptan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000306	0.000359	CcSEcCtD
Naratriptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000306	0.000358	CcSEcCtD
Naratriptan—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000305	0.000357	CcSEcCtD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000304	0.00397	CbGpPWpGaD
Naratriptan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.000349	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000296	0.00386	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000296	0.00386	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000295	0.00386	CbGpPWpGaD
Naratriptan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000295	0.000346	CcSEcCtD
Naratriptan—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.000346	CcSEcCtD
Naratriptan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.000345	CcSEcCtD
Naratriptan—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.000344	CcSEcCtD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00029	0.00378	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00029	0.00378	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00029	0.00378	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00029	0.00378	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000289	0.00378	CbGpPWpGaD
Naratriptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000289	0.000338	CcSEcCtD
Naratriptan—HTR1D—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000289	0.00377	CbGpPWpGaD
Naratriptan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.000333	CcSEcCtD
Naratriptan—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000283	0.00369	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000282	0.00368	CbGpPWpGaD
Naratriptan—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000282	0.00033	CcSEcCtD
Naratriptan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000281	0.00033	CcSEcCtD
Naratriptan—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00028	0.000328	CcSEcCtD
Naratriptan—HTR1F—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000279	0.00364	CbGpPWpGaD
Naratriptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000278	0.000326	CcSEcCtD
Naratriptan—HTR1F—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000278	0.00363	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000277	0.00362	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000276	0.0036	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000267	0.00348	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000267	0.00348	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000266	0.00347	CbGpPWpGaD
Naratriptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000265	0.000311	CcSEcCtD
Naratriptan—MAOA—Metabolism—TAT—acquired immunodeficiency syndrome	0.000263	0.00344	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000261	0.00341	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000261	0.00341	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000261	0.00341	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000261	0.0034	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000259	0.00339	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000256	0.00334	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000252	0.00329	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00025	0.00326	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000241	0.00315	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000237	0.0031	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000237	0.0031	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000235	0.00306	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000232	0.00302	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000225	0.00294	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000224	0.00292	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000221	0.00288	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000221	0.00288	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00022	0.00288	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00022	0.00288	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000215	0.00281	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00021	0.00274	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000203	0.00265	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000199	0.0026	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000199	0.00259	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000198	0.00259	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000196	0.00256	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000195	0.00254	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000181	0.00236	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000179	0.00234	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000178	0.00233	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000178	0.00232	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000178	0.00232	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000175	0.00228	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000174	0.00227	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000172	0.00224	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000171	0.00223	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000171	0.00223	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000168	0.00219	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000167	0.00218	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000167	0.00218	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000167	0.00218	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000167	0.00218	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000165	0.00215	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000164	0.00214	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000164	0.00214	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000163	0.00212	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000161	0.00211	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000158	0.00206	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000154	0.00201	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000152	0.00198	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000152	0.00198	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000151	0.00197	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000151	0.00197	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000149	0.00195	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000149	0.00194	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000149	0.00194	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000146	0.0019	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00014	0.00183	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00014	0.00183	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000138	0.00181	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000133	0.00174	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000133	0.00173	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000127	0.00166	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000127	0.00166	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000127	0.00166	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000125	0.00163	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000125	0.00163	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000125	0.00163	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000124	0.00163	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000123	0.0016	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00012	0.00157	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000118	0.00154	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000115	0.00151	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000115	0.0015	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000115	0.0015	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000114	0.00148	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000113	0.00148	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000113	0.00148	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000113	0.00148	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000112	0.00146	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000111	0.00145	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000107	0.00139	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000105	0.00138	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000105	0.00137	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000104	0.00136	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000103	0.00135	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000103	0.00135	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000102	0.00133	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.61e-05	0.00125	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.53e-05	0.00124	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.48e-05	0.00124	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.4e-05	0.00123	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.34e-05	0.00122	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.34e-05	0.00122	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.96e-05	0.00117	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.96e-05	0.00117	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.78e-05	0.00115	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.78e-05	0.00115	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.61e-05	0.00112	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.54e-05	0.00112	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.48e-05	0.00111	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.86e-05	0.00103	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.76e-05	0.00101	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.11e-05	0.000928	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.82e-05	0.00089	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.72e-05	0.000877	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.69e-05	0.000873	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.69e-05	0.000873	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.68e-05	0.000872	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.62e-05	0.000864	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.58e-05	0.000859	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.48e-05	0.000846	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.14e-05	0.000802	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.02e-05	0.000785	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.01e-05	0.000784	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.88e-05	0.000768	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.55e-05	0.000725	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.52e-05	0.000721	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.09e-05	0.000664	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.01e-05	0.000654	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.94e-05	0.000644	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—acquired immunodeficiency syndrome	4.59e-05	0.0006	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.58e-05	0.000598	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.48e-05	0.000585	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.55e-05	0.000463	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.53e-05	0.000461	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.48e-05	0.000454	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.46e-05	0.000452	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.26e-05	0.000426	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.65e-05	0.000346	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.63e-05	0.000344	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.09e-05	0.000272	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.04e-05	0.000267	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.56e-05	0.000203	CbGpPWpGaD
